# Abatacept as GVHD Prophylaxis Phase 2

> **NCT01743131** · PHASE2 · COMPLETED · sponsor: **Boston Children's Hospital** · enrollment: 186 (actual)

## Conditions studied

- Graft vs Host Disease
- Malignancy

## Interventions

- **DRUG:** Abatacept
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01743131
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-01
- **Primary completion:** 2018-06-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743131, "Abatacept as GVHD Prophylaxis Phase 2". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01743131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*